Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation

Maansi Joshi,John Taper,Cecily Forsyth,Philip A. Rowlings,Philip Campbell,Philip Crispin,Michael Harvey,Craig Underhill,Angela Bayley,Karen Byth,Gillian Huang,Mark Hertzberg

Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation

2019

Maansi Joshi
John Taper
Cecily Forsyth
Philip A. Rowlings
Philip Campbell
Philip Crispin
Michael Harvey
Craig Underhill
Angela Bayley
Karen Byth
Gillian Huang
Mark Hertzberg

AbstractPatients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous stem cell transplantation (autoSCT) have poor survival. Thirty transplant-ineligible pat...

Keywords:

Large-cell lymphoma
Internal medicine
Refractory
Oncology
Autologous stem-cell transplantation
Medicine
Rituximab
Refractory Diffuse Large B-Cell Lymphoma
Lymphoma
Stem cell
Immunology
Transplantation
Hematology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations